Risk of developing a carboplatin infusion reaction over cumulative cycles of therapy for BRCA mutation carriers versus non-carriers

Reprinted by permission from Macmillan Publishers Ltd on behalf of Cancer Research UK: British Journal of Cancer. Moon DH, Lee JM, Noonan AM, et al. Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions. Br J Cancer 2013; 109:1072. Copyright © 2013. www.nature.com/bjc.